Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
U6 small nuclear RNA 1 (RNU6-1) is a non-coding RNA that forms a catalytic core component of the spliceosome, the molecular machine responsible for the removal of introns from pre-messenger RNA (pre-mRNA) in eukaryotic cells[2][3]. U6 snRNA is highly conserved across species, reflecting its essential role in gene expression and cell viability[2][3][4]. It is transcribed by RNA polymerase III and, in humans, is approximately 107 nucleotides long[5][7]. U6 snRNA undergoes complex biogenesis and structural rearrangements to interact with multiple spliceosomal proteins and other small nuclear RNAs (such as U4 and U2), coordinating the two-step splicing chemistry necessary for intron excision[2][3]. While U6 RNA has been employed as an internal control in molecular assays (such as RT-qPCR), recent studies indicate its expression can be highly variable between tissues and disease states, questioning its suitability as a normalization reference[1]. U6 does not function as a drug target, enzyme, receptor, or transporter, but its proper biogenesis and function are critical for normal RNA processing and, by extension, normal cellular function[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 1 (RNU6-1).